Form 4 for APRE Aprea Therapeutics, Inc.
Accepted 2023-02-27 00:00:00 ET · period of report 2023-02-27 · accession 0001104659-23-026159 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-02-27 | 2023-02-27 | APRE | Hamill John P. | CFO, SrVP, Prin Fin, Acct Ofcr | A - Grant | $5.25 | +1,000 | 14.5K | +7% | +$5,250 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-27 | A | A | 1,000 | $5.25 | 14,493 | D | — | — | (F1) Effective February 13, 2023, the Issuer completed a 1-for-20 reverse stock split (the "Reverse Stock Split") of its outstanding Common Stock. The number of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split. |